2020 ACCP Virtual Journal Club June | Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval-An Analysis of ECGs From the IQ-CSRC Study-On Demand
Evaluation of the Effect of QT-Positive Drugs on the JTpeak Interval-An Analysis of ECGs From the IQ-CSRC Study- On Demand
ACCP Virtual Journal Club Webinars
Live Session: Wednesday, June 17, 2020 from 2:00-3:00 PM ET
On Demand: June 17, 2020 to June 17, 2023
See Handouts tab for Continuing Education information on IPCE credits.
Borje Darpo, MD, PhD
Chief Scientific Officer, Cardiac Safety, ERT
Borje Darpo, MD, PhD is board certified in cardiology and previously Associate Professor of Cardiology at the Karolinska Institute, Sweden. He specialized in clinical electrophysiology and presented his thesis on the clinical development of an antiarrhythmic drug in 1995. In 1998 he joined Pharmacia and has held positions as Clinical Program Leader in Cardiovascular, Regional Head of EU for Clinical Pharmacology and Senior Director in Pfizer’s Clinical Technologies group in Sandwich, UK. Between April 2004 and March 2006, Dr Darpo held the position as Chief Medical Officer of Daiichi Medical Research in UK and USA.
In 1997 Dr. Darpo participated as a member of the expert committee that drafted the CPMP’s “Points to Consider” on clinical QT assessment. Dr Darpo represented the European Pharmaceutical industry (EFPIA) as deputy topic leader of the ICH E14 Expert Working Group and Implementation Working Group between 2000 and 2008.
As the co-chair of the Scientific Oversight committee of CSRC, Dr Darpo led and coordinated the successful IQ-CSRC study, which contributed to the revision of the ICH E14 clinical guidance on QT assessment. He currently serves as the Chief Scientific Officer, Cardiac Safety of ERT, and works with sponsor clients on strategies for ECG assessment in clinical development and design and analysis of ECG studies.